Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF neoadjuvant chemotherapy followed by weekly cisplatin chemoradiation for locally advanced nasopharyngeal carcinoma
ACTRN12611000835943Phase 2Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinical response rate. Started Aug 2011; status: recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ACTRN12611000835943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000835943.